Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Ajanta Explains FDA Sildenafil Action, Shares Rebound

Executive Summary

Ajanta Pharma regained some lost ground on Indian bourses after the company clarified its position on an FDA import alert against its sildenafil citrate product and reported a healthy set of earnings for the third quarter ended December 2016.

Advertisement

Related Content

More Indian drugs detained in EU as FTA talks progress ahead of summit

Topics

Advertisement
UsernamePublicRestriction

Register

SC098094

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel